Wellington Management Group LLP Has $55.98 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Wellington Management Group LLP decreased its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 15.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,234,455 shares of the company's stock after selling 751,521 shares during the quarter. Wellington Management Group LLP owned approximately 4.92% of Syndax Pharmaceuticals worth $55,979,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. R Squared Ltd bought a new position in Syndax Pharmaceuticals in the 4th quarter worth about $26,000. Virtus ETF Advisers LLC grew its position in Syndax Pharmaceuticals by 18.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock worth $70,000 after purchasing an additional 827 shares during the last quarter. Cape Investment Advisory Inc. grew its position in Syndax Pharmaceuticals by 157.1% in the 4th quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company's stock worth $85,000 after purchasing an additional 3,927 shares during the last quarter. KBC Group NV grew its position in Syndax Pharmaceuticals by 104.8% in the 4th quarter. KBC Group NV now owns 6,954 shares of the company's stock worth $92,000 after purchasing an additional 3,559 shares during the last quarter. Finally, Optimize Financial Inc bought a new position in shares of Syndax Pharmaceuticals in the fourth quarter valued at approximately $152,000.

Syndax Pharmaceuticals Stock Performance

NASDAQ:SNDX traded up $0.27 during trading hours on Tuesday, hitting $11.25. The stock had a trading volume of 285,574 shares, compared to its average volume of 1,784,874. Syndax Pharmaceuticals, Inc. has a one year low of $8.58 and a one year high of $25.07. The company has a market cap of $968.03 million, a price-to-earnings ratio of -3.10 and a beta of 0.82. The business's 50 day moving average is $11.44 and its 200-day moving average is $13.36.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.06. The firm had revenue of $20.04 million during the quarter, compared to the consensus estimate of $15.88 million. During the same period in the previous year, the company posted ($0.85) EPS. The firm's revenue for the quarter was up 1900.0% on a year-over-year basis. On average, sell-side analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SNDX. Wall Street Zen raised shares of Syndax Pharmaceuticals to a "sell" rating in a research note on Tuesday, May 6th. JPMorgan Chase & Co. lifted their target price on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a research note on Thursday, March 20th. HC Wainwright reaffirmed a "buy" rating and issued a $51.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Scotiabank lifted their price objective on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a "sector perform" rating in a research note on Tuesday, May 6th. Finally, Citigroup reduced their price objective on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $35.91.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).